Manufacturer
PHARMANIAGA LIFESCIENCE SDN. BHD.
Contents
Amikacin
Indication
Severe Gram-negative infections, Uncomplicated urinary tract infections.
Instruction
Adult: IM/IV Severe gm-ve infections 15 mg/kg/day as a single or in 2 divided doses. Max: 1.5 g/day. Uncomplicated UTI 7.5 mg/kg/day in 2 divided doses.
Drug interaction
Additive effect w/ other neurotoxic, ototoxic or nephrotoxic agents (e.g. bacitracin, cisplatin, amphotericin B, ciclosporin, tacrolimus, cefaloridine, paromomycin, viomycin, polymyxin B, colistin, vancomycin, and other aminoglycosides). Enhanced toxicity w/ rapidly acting diuretics (e.g. furosemide, ethacrynic acid). Increased creatinine serum level w/ cephalosporins. Indomethacin may increase the plasma concentration of amikacin in neonates. Increased risk of hypocalcaemia w/ biphosphonates. Increased risk of nephrotoxicity and possibly ototoxicity w/ platinum compounds. Increased risk of neuromuscular blockade and consequent resp depression w/ anaesth or muscle relaxants (e.g. ether, halothane, d-tubocurarine, succinylcholine decamethonium, atracurium, rocuronium, vecuronium).
Malaysia
